No Prescription |
 |
 | ||
|
Ovestin Generic Oestriol |
|
| ||
No Prescription » Prescription Drugs 12 » Ovestin Generic Oestriol Indications:Atrophy of the lower urogenital tract related to oestrogen deficiency notably1.For the treatment of vaginal complaints such as dyspareunia dryness and itching. for the prevention of recurrent infections of the vagina and lower urinary tract. 2.In the management of micturition complaints (such as frequency and dysuria) and mild urinary incontinence. Pre- and postoperative therapy in postmenopausal women undergoing vaginal surgery.3.Climacteric complaints such as hot flushes and night sweating.4.A diagnostic aid in case of a doubtful atrophic cervical smear.5.Infertility due to cervical hostility.Dosage And Administration:Dosage:Atrophy of the lower urogenital tract: 4-8mg per day for the first weeks followed by a gradual reduction based on relief of symptoms until a maintenance dosage (e.g. 1-2mg per day) is reached. Pre- and postoperative therapy in postmenopausal women undergoing vaginal surgery:4-8mg per day in the 2 weeks before surgery; 1-2mg per day in the 2 weeks after surgery.Climacteric complaints such as hot flushes and night sweating:4-8mg per day during the first weeks followed by a gradual reduction. The lowest effective dosage should be used. In case of long-term treatment in women with an intact uterus monitoring of the endometrium or alternatively concomitant use of a progestagen is recommended A diagnostic aid in case of a doubtful atrophic cervical smear2-4mg per day for 7 days before taking the next smear.Infertility due to cervical hostilityIn general 1-2mg per day on days 6-15 of the menstrual cycle. However for some patients dosages as low as 1mg per day are sufficient whereas others may need up to 8mg per day. Therefore the dosage should be increased each month until an optimal effect on the cervical mucus is obtained.AdministrationA missed dose should be taken as soon as remembered unless it is more than 12 hours overdue. In the latter case the missed dose should be skipped and the next dose should be taken at the normal time. The tablets should be swallowed with some water or other drink preferably at the same time every day. It is important that the total daily dose is taken at one time.For initiation and continuation of treatment of postmenopausal symptoms the lowest effective dose for the shortest duration of time should be used (see also Warnings and Precautions).In women not taking HRT or women who switch from a continuous combined HRT product treatment with OVESTIN may be started on any day. Women who switch from cyclic HRT regimen should start OVESTIN treatment one week after completion of the cycle. Buy Ovestin Generic Oestriol and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About Ovestin Generic Oestriol: Product Type: Prescription Drugs 12 Ovestin ( Generic Oestriol ) Ovestin (Generic Oestriol) Generic Oestriol 2mg Generic Oestriol Ovestin
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
